Transmitted HIV-1 drug resistance among young men of color who have sex with men: A multicenter cohort analysis

Journal of Adolescent Health

Volumn 48, Issue 1, 2011, Pages 94-99

  Hightow Weidman, Lisa B ^a   Hurt, Christopher B ^a   Phillips II, Gregory ^b   Jones, Karen ^b   Magnus, Manya ^b   Giordano, Thomas P ^c   Outlaw, Angulique ^d   Ramos, Daniel ^e   Enriquez Bruce, Elizabeth ^f   Cobbs, Will ^g   Wohl, Amy ^h   Tinsle, Melinda ⁱ  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e East Bay Community Recovery Project   (United States)

^f Bronx AIDS Services Inc   (United States)

^g Working for Togetherness Inc   (United States)

^h LOS ANGELES COUNTY DEPARTMENT OF PUBLIC HEALTH   (United States)

ⁱ HAB   (United States)

Author keywords

HIV; Minority; MSM

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; ETHNICITY; GENOTYPE; GEOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MULTICENTER STUDY (TOPIC); MUTATION; PRIORITY JOURNAL; RACE DIFFERENCE; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; GENES, POL; GENOTYPE; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MALE; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; SEXUALLY TRANSMITTED DISEASES; UNITED STATES; YOUNG ADULT;

EID: 78650697680     PISSN: 1054139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jadohealth.2010.05.011     Document Type: Article

References (40)

1. J.E. Gallant, E. DeJesus, and J.R. Arribas Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV N Engl J Med 354 2006 251 260
2. V. DeGruttola, L. Dix, and R. D'Aquila The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan Antivir Ther 5 2000 41 48
3. S.J. Little, S. Holte, and J.P. Routy Antiretroviral-drug resistance among patients recently infected with HIV N Engl J Med 347 2002 385 394
4. I. Derdelinckx, K. Van Laethem, and B. Maes Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response J Acquir Immune Defic Syndr 37 2004 1664 1666
5. P. Cane, I. Chrystie, and D. Dunn Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study BMJ 331 2005 1368
6. P.E. Sax, R. Islam, and R.P. Walensky Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis Clin Infect Dis 41 2005 1316 1323
7. D. Pillay, K. Bhaskaran, and S. Jurriaans The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy AIDS 20 2006 21 28
8. G. Poggensee, C. Kucherer, and J. Werning Impact of transmission of drug-resistant HIV on the course of infection and the treatment success Data from the German HIV-1 Seroconverter Study HIV Med 8 2007 511 519
9. S.J. Little, S.D. Frost, and J.K. Wong Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection J Virol 82 2008 5510 5518
10. B.G. Brenner, J.P. Routy, and M. Petrella Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection J Virol 76 2002 1753 1761
11. B.G. Brenner, M. Roger, and J.P. Routy High rates of forward transmission events after acute/early HIV-1 infection J Infect Dis 195 2007 951 959
12. A.M. Wensing, D.A. van de Vijver, and G. Angarano Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management J Infect Dis 192 2005 958 966
13. H.S. Weinstock, I. Zaidi, and W. Heneine The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities J Infect Dis 189 2004 2174 2180
14. UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study, UK Register of HIV Seroconverters Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom AIDS 21 2007 1035 1039
15. SPREAD programme Transmission of drug-resistant HIV-1 in Europe remains limited to single classes AIDS 22 2008 625 635
16. B. Masquelier, K. Bhaskaran, and D. Pillay Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: Data from seroconverters in the CASCADE collaboration from 1987 to 2003 J Acquir Immune Defic Syndr 40 2005 505 511
17. R.M. Grant, F.M. Hecht, and M. Warmerdam Time trends in primary HIV-1 drug resistance among recently infected persons JAMA 288 2002 181 188
18. W. Wheeler, K. Mahle, and U. Bodnar Antiretroviral Drug-resistance mutations and subtypes in drug-nave persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006 2007 CROI Los Angeles, CA
19. D. Bennett, I. Zaidi, and W. Heneine Prevalence of mutations associated with antiretroviral drug resistance among recently diagnosed persons with HIV, 1998-2000 2002 CROI Seattle, WA
20. C.M. Wilson, J. Houser, and C. Partlow The REACH (Reaching for Excellence in Adolescent Care and Health) project: Study design, methods, and population profile J Adolesc Health 29 2001 8 18
21. R.M. Viani, L. Peralta, and G. Aldrovandi Prevalence of primary HIV-1 drug resistance among recently infected adolescents: A multicenter adolescent medicine trials network for HIV/AIDS interventions study J Infect Dis 194 2006 1505 1509
22. H.I. Hall, R. Song, and P. Rhodes Estimation of HIV incidence in the United States JAMA 300 2008 520 529
23. CDC HIV/AIDS among youth 2008 CDC HIV/Aids Facts Sheet
24. H.I. Hall, R.H. Byers, Q. Ling, and L. Espinoza Racial/ethnic and age disparities in HIV prevalence and disease progression among men who have sex with men in the United States Am J Public Health 97 2007 1060 1066
25. CDC Subpopulation estimates from the HIV incidence surveillance systemUnited States Morb Mortal Wkly Rep 57; 2006 2008 9859
26. D.E. Bennett, R.J. Camacho, and D. Otelea Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update PLoS ONE 4 2009 e4724
27. R.W. Shafer, S.Y. Rhee, and D. Pillay HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance AIDS 21 2007 215 223
28. H. Green, P. Tilston, and E. Fearnhill The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom J Acquir Immune Defic Syndr 49 2008 196 204
29. http://hivdb.stanford.edu
30. M. Harris, J.B. Angel, and J.G. Baril Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults Can J Infect Dis Med Microbiol 20 2009 e24 e34
31. V.E. Stone, J. Jordan, J. Tolson, R. Miller, and T. Pilon Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: Self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence J Acquir Immune Defic Syndr 36 2004 808 816
32. P. Halkitis, J. Palamar, and P. Mukherjee Analysis of HIV medication adherence in relation to person and treatment characteristics using hierarchical linear modeling AIDS Patient Care STDS 22 2008 323 335
33. J.J. Parienti, D.R. Bangsberg, R. Verdon, and E.M. Gardner Better adherence with once-daily antiretroviral regimens: A meta-analysis Clin Infect Dis 48 2009 484 488
34. J.M. Molina Efficacy and safety of once-daily regimens in the treatment of HIV infection Drugs 68 2008 567 578
35. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and AdolescentsNovember 3, 2008 http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf Accessed May 28, 2009
36. M. Sturmer, H.W. Doerr, A. Berger, and P. Gute Is transmission of HIV-1 in non-viraemic serodiscordant couples possible? Antivir Ther 13 2008 729 732
37. H. Zhang, G. Dornadula, and M. Beumont Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy N Engl J Med 339 1998 1803 1809
38. P.S. Sullivan, L. Salazar, S. Buchbinder, and T.H. Sanchez Estimating the proportion of HIV transmissions from main sex partners among men who have sex with men in five US cities AIDS 23 2009 1153 1162
39. L.B. Hightow-Weidman, C.E. Golin, and K. Green Identifying people with acute HIV infection: Demographic features, risk factors, and use of health care among individuals with AHI in North Carolina AIDS Behav 13 2009 1075 1083
40. CDC HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men: Five U.S. cities, June 2004-April 2005 Morb Mortal Wkly Rep 52 2005 597 601